Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

1.495 +0.025 (+1.70%)
Delayed Quote Updated: 3:56 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Participation in 2026 BIO International Convention
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
From Enveric Biosciences
Via Business Wire
News headline image
SmallCap Emerge: ENVB, SMX, ANY, ELPW Across High-Growth Sectors
Via AB Newswire
Topics Artificial Intelligence Economy
News headline image
Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum
From Enveric Biosciences
Via Business Wire
News headline image
Kartoon Studios (NYSE: TOON) Gaining Momentum Alongside CMND, ENVB, WLDS, ANY – See Why?
Via AB Newswire
Topics Intellectual Property
News headline image
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Registration of Five Trademarks
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Patent Issuance
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds
From Enveric Biosciences, Inc
Via Business Wire
News headline image
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.